# Intravascular Imaging Incorporated (i3)

> Intravascular Imaging Incorporated (i3) is a Wilton, Connecticut medical device company building a next-generation coronary imaging catheter. Its 3-French NIRF-IVUS catheter fuses intravascular ultrasound (IVUS), the clinical standard for guiding stent placement, with near-infrared fluorescence (NIRF) molecular imaging in a single device. The combination lets cardiologists see not just the anatomy of a coronary artery but the biology inside it - plaque inflammation, arterial dissections, transplant vasculopathy, and fibrin in unhealed stents. Spun out of work at Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, i3 aims to upgrade percutaneous coronary intervention (PCI) by helping doctors look beyond anatomy.

- **Founded:** 2018
- **Headquarters:** Wilton, Connecticut, United States
- **Founders:** Farouc A. Jaffer (Co-Founder; interventional cardiologist, Professor of Medicine and Director of Coronary Intervention at MGH/Harvard Medical School), Vasilis Ntziachristos (Co-Founder; biological/molecular imaging researcher, Professor at Technical University of Munich), R. Scott Jones (Chairman & CEO; medical device industry veteran)
- **Team size:** Small (reported ~2 employees in directory data; core founding team plus scientific leadership)
- **Products:** 3-French NIRF-IVUS Imaging Catheter, NIRF-IVUS Imaging System
- **Notable:** Developed a miniaturized 3-French integrated NIRF-IVUS catheter, small enough for human coronary arteries., Demonstrated favorable results in ex-vivo human coronary arteries and in vivo preclinical studies., Built on peer-reviewed research in molecular-structural intravascular imaging (e.g., published in 2021 demonstrating an integrated NIRF-ultrasound catheter).

## Products & services

- **3-French NIRF-IVUS Imaging Catheter** — A miniaturized, integrated intravascular catheter combining intravascular ultrasound (IVUS) with near-infrared fluorescence (NIRF) molecular imaging in a single pullback. Co-registers plaque anatomy with molecular and cellular signals to visualize coronary lesion progression, arterial dissections, coronary transplant vasculopathy, plaque inflammation, and fibrin in unhealed stents. Tested in ex-vivo human coronary arteries and in vivo preclinical studies.
- **NIRF-IVUS Imaging System** — The console and software platform that drives the catheter and renders co-registered longitudinal maps and cross-sectional views with a NIRF-signal overlay, positioned as an upgrade to the worldwide installed base of IVUS systems.

## Achievements

- Developed a miniaturized 3-French integrated NIRF-IVUS catheter, small enough for human coronary arteries.
- Demonstrated favorable results in ex-vivo human coronary arteries and in vivo preclinical studies.
- Built on peer-reviewed research in molecular-structural intravascular imaging (e.g., published in 2021 demonstrating an integrated NIRF-ultrasound catheter).
- Launched Series A financing in July 2022 to advance GMP manufacturing and pivotal human studies.

## Latest updates

- **2022-07** — Announced the launch of its 3-French NIRF-IVUS imaging catheter with favorable ex-vivo human coronary tests, and launched Series A financing to fund GMP manufacturing and the path to human pivotal studies and FDA submission.

## Links

- Website: https://i3-nirf.com
- LinkedIn: http://www.linkedin.com/company/intravascular-imaging-incorporated-i3-

---

Profile page: https://yespress.io/intravascular-imaging-incorporated-i3
Published by YesPress — https://yespress.io
Last updated: 2026-06-14